Amber T. Bradley, Ph.D. - Publications
Affiliations: | 2014 | Cell and Molecular Pharmacology | Medical University of South Carolina, Charleston, SC, United States |
Area:
Molecular Biology, Cell Biology, Pharmacology, Oncology| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2017 | Eblen ST, Bradley A. MOAP-1, UBR5 and cisplatin resistance in ovarian cancer. Translational Cancer Research. 6: S18-S21. PMID 29607295 DOI: 10.21037/Tcr.2017.02.01 | 0.668 | |||
| 2014 | Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN, Eblen ST. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 35: 1100-9. PMID 24379240 DOI: 10.1093/Carcin/Bgt489 | 0.687 | |||
| 2013 | Liu Y, Conaway LN, Bethard JR, Bradley AT, Eblen S. Abstract 4283: Src phosphorylates splicing factor 45 (SPF45) and regulates SPF45 nucleocytoplasmic shuttling, cell migration and invasion. Cancer Research. 73: 4283-4283. DOI: 10.1158/1538-7445.Am2013-4283 | 0.6 | |||
| 2011 | Bradley AT, Zheng H, Ziebarth A, Sakati W, Eier S, Lopez-Berestein G, Sood AK, Landen C, Eblen ST. Abstract 1649: The E3 ubiquitin ligase EDD regulates platinum resistance and is a novel therapeutic target for epithelial ovarian cancer Cancer Research. 71: 1649-1649. DOI: 10.1158/1538-7445.Am2011-1649 | 0.688 | |||
| 2011 | Ziebarth A, Zheng H, Bradley A, Sakati W, Eier S, Lopez-Berestein G, Sood A, Eblen S, Landen C. The ubiquitin ligase EDD mediates platinum resistance and is a target for therapy in epithelial ovarian cancer Gynecologic Oncology. 120: S26-S27. DOI: 10.1016/J.Ygyno.2010.12.066 | 0.653 | |||
| Show low-probability matches. | |||||